Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  MAP Pharmaceuticals Inc.    MAPP   US56509R1086

SummaryQuotesChart AnalysisNewsCalendarCompany 
News SummaryMost relevantAll news 

Map Pharmaceuticals Plans FDA Meeting To Discuss Manufacturing Issues

04/12/2012 | 05:18pm US/Eastern

Map Pharmaceuticals Inc. (>> MAP Pharmaceuticals Inc.) plans to meet with the Food and Drug Administration during the current quarter to discuss manufacturing issues that are preventing approval of its migraine medication Levadex.

The FDA in March sent a complete response letter to the biopharmaceutical company that required Map Pharmaceuticals to address manufacturing issues, chemistry and controls issues found in an inspection of the drug maker's third-party manufacturer.

Investors have been awaiting the agency's decision on the usability of Map's inhalable drug, which delivers a common migraine treatment in an aerosol format.

President and Chief Executive Timothy S. Nelson said the company continues to work closely with partner Allergan Inc. (AGN), as it seeks to resolve the issues as quickly as possible. Allergan has a deal with Map Pharmaceuticals to jointly promote Levadex.

The company also announced that it recently was issued a third patent related to Levadex.

Map shares closed Thursday at $13.14, down 1.2%, and were inactive in after-hours trading. The stock is off nearly 27% from a 2-year high last month before the company received the FDA's complete response letter.

 
   -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com 

Stocks mentioned in the article : MAP Pharmaceuticals Inc.
React to this article
Latest news on MAP PHARMACEUTICALS INC.
2013DJAllergan to Sell Lap-band Business; Profit Up 20% -- Update
2013DJALLERGAN, INC. : Allergan Agrees to Sell Obesity Unit; 3rd-Quarter Profit Up 20%
2013DJStrong Botox Sales Help Lift Allergan's Profits 16%
2013DJAllergan 4th-Quarter Profit Rose 16% Amid Growing Revenue, Fewer Charges
2013 MAP PHARMACEUTICALS INC. : Faruqi & Faruqi, LLP is Seeking More Cash for the Sha..
2013 MAP PHARMACEUTICALS INC. : Morgan & Morgan Announces Investigation of MAP Pharma..
2013 MAP PHARMACEUTICALS INC. : Law Office of Brodsky & Smith, LLC Announces Investig..
2013 MAP PHARMACEUTICALS INC. : Ryan & Maniskas, LLP Announces Investigation of MAP P..
2013 MAP PHARMACEUTICALS INC. : Harwood Feffer LLP Announces Investigation of MAP Pha..
2013 MAP PHARMACEUTICALS INC. : Rigrodsky & Long, P.A. Announces Investigation Of MAP..
Advertisement
Chart
Duration : Period :
MAP Pharmaceuticals Inc. Technical Analysis Chart | MAPP | US56509R1086 | 4-Traders
Dynamic quotes  
ON
| OFF